Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)
Acadia Pharmaceuticals (ACAD) reported Phase 2 results for remlifanserin in treating Alzheimer’s disease psychosis. The 60 mg dose showed efficacy vs. placebo, while the 30 mg dose did not. The company plans to continue Phase 3 trials, focusing on the 60 mg dose. Remlifanserin demonstrated a favorable safety profile. Acadia will present detailed results at the CTAD conference in November 2026.
How this was made
The 30-second read
Why it matters
The Phase 2 data provide the first efficacy signal for remlifanserin, guiding Phase 3 design and investor sentiment.
Market read
The announcement may move ACAD stock and influence peer biotech valuations in the neuro‑psychiatric space.
What to watch
Regulatory pathway uncertainties and competition from other 5‑HT2A inverse agonists could dampen long‑term upside.
Background
Acadia is the only FDA‑approved provider of treatments for Parkinson’s disease psychosis and is expanding into Alzheimer’s disease psychosis with remlifanserin.
Ticker impact
Acadia Pharmaceuticals announced Phase 2 topline results for remlifanserin showing modest efficacy and a favorable safety profile.
possible short‑term upside on the 60 mg data, but volatility if later Phase 3 fails to meet endpoints.
Phase 2 results are a material catalyst for a biotech, yet the primary endpoint missed conventional significance (p=0.0603). Market reaction will depend on investor risk appetite and upcoming Phase 3 design.
Market effects
Adds modest optimism to the Alzheimer’s disease psychosis therapeutic space, potentially boosting peer biotech valuations.
Limited to U.S. biotech sector; no broader regional effect.
Relevant to global investors tracking neuro‑psychiatric drug pipelines.
Counterpoint
The modest effect size and borderline p‑value may signal over‑hyped expectations; a negative surprise in Phase 3 could trigger a sharp sell‑off.
Key entities
- CompanyAcadia Pharmaceuticals Inc.
Biopharma developing remlifanserin for neuro‑psychiatric indications.
- ExecutiveCatherine Owen Adams
CEO of Acadia, quoted on the trial results.
